You Got a Tumor Panel Report. Now What?

Your oncologist orders a tumor panel. A few weeks later, you get a report -- maybe from Foundation Medicine, Tempus, or Guardant Health. It's full of gene names, variant descriptions, biomarker results, and therapy suggestions. Your doctor spends maybe five minutes on it during your next appointment. They circle one or two things. The rest goes unexplained.

You go home and Google "EGFR L858R mutation." You find a mix of research papers you can't parse, forum posts from other patients, and conflicting information about what it means for treatment. You wonder if there are clinical trials you should know about. You wonder if your current treatment is the best option.

This is the reality for millions of cancer patients. The data exists. The interpretation gap is enormous.

What's actually in your tumor panel report

A comprehensive genomic profiling report typically includes three categories of findings:

• Somatic mutations -- Genetic changes found in the tumor (not inherited). These include missense mutations, deletions, insertions, fusions, and amplifications in genes like EGFR, KRAS, BRAF, ALK, ROS1, PIK3CA, and dozens of others. Each mutation may or may not be "actionable" -- meaning there's an approved or investigational therapy that targets it.
• Biomarkers -- TMB (tumor mutational burden), MSI (microsatellite instability), and PD-L1 expression. These determine eligibility for immunotherapy. A TMB-High or MSI-High result is a strong signal for checkpoint inhibitor therapy, regardless of cancer type.
• Prior treatments and lab recommendations -- Some reports include the lab's own therapy suggestions based on the mutation profile. These are helpful but not personalized to your full medical history.

The problem: reading a tumor panel report requires understanding cancer genomics, drug mechanisms, evidence levels, and clinical trial landscapes. Your oncologist knows this, but they're managing dozens of patients. The report lands in your patient portal with no translation layer.

How Vitalix turns a PDF into actionable intelligence

When you upload your tumor panel PDF to Vitalix, here's what happens in about 60 seconds:

1. AI extracts every finding from the report

Vitalix uses AI vision to read the PDF and extract all mutations (gene, variant, variant type, VAF), biomarkers (TMB, MSI, PD-L1), cancer type, stage, specimen type, prior treatments, and lab-recommended therapies. No manual data entry. It works with FoundationOne, Tempus, Guardant360, and other standard report formats.

2. Every mutation is classified by actionability

Each somatic mutation is run through three clinical databases in parallel:

• OncoKB (Memorial Sloan Kettering) -- Classifies mutations by evidence level. Level 1 means there's an FDA-approved therapy for that specific mutation in your cancer type. Level 2 means standard-of-care based on strong evidence. Level 3 means investigational therapies with clinical evidence. Level 4 means biological evidence only.
• CIViC (Clinical Interpretation of Variants in Cancer) -- Open-source evidence database with clinical assertions, AMP evidence levels, NCCN guideline references, and molecular profile scores.
• COSMIC (Catalogue of Somatic Mutations in Cancer) -- Mutation frequency data across cancer types. Knowing that your mutation appears in 15% of lung adenocarcinomas vs 0.1% is clinically relevant context.

The result: instead of a list of gene names, you see each mutation color-coded by actionability with matched therapies and evidence levels. The mutations that matter most are at the top.

3. Therapy matching connects mutations to treatments

For each actionable mutation, Vitalix surfaces:

• FDA-approved therapies -- Drugs approved for your specific mutation and cancer type (OncoKB Level 1-2). These are the treatments your oncologist is most likely already considering.
• Investigational therapies -- Drugs with clinical evidence but not yet approved for your specific indication (OncoKB Level 3-4, CIViC sensitivity evidence). These are the options your oncologist may not have mentioned because they require clinical trial enrollment.
• Biomarker-matched immunotherapy -- If your TMB is high, MSI is high, or PD-L1 expression is elevated, Vitalix flags checkpoint inhibitor eligibility regardless of your primary cancer type.

4. Clinical trial search finds trials you're eligible for

Vitalix searches ClinicalTrials.gov using multiple query strategies:

• Mutation-specific searches (e.g., "EGFR L858R" + your cancer type)
• Biomarker-matched trials (TMB-High, MSI-High, PD-L1 positive)
• Post-prior-treatment trials (trials for patients who've already received your previous treatments)
• Basket trials (mutation-agnostic trials that accept any solid tumor with your biomarker profile)

Results are deduplicated, ranked by relevance, and filtered to recruiting trials. For each trial, the AI assesses your preliminary eligibility based on your cancer type, mutations, biomarkers, and prior treatments.

5. Your inherited genetics add a safety layer

If you've uploaded 23andMe or AncestryDNA data, Vitalix cross-references your germline genetics with your tumor findings. This catches things that separate systems miss:

• A BRCA1 germline mutation combined with a BRCA-associated tumor profile flags PARP inhibitor eligibility
• DPYD poor metabolizer status raises a critical safety alert if fluoropyrimidine chemotherapy (5-FU, capecitabine) is being considered -- this drug can be life-threatening for DPYD-deficient patients
• Lynch syndrome (germline MMR gene mutations) combined with MSI-High tumor status strengthens the case for immunotherapy
• Any pharmacogenomic interaction between your genetics and your current cancer medications is flagged automatically

These cross-references happen in the background. You don't need to ask for them.

Beyond the report: tracking treatment and recovery

Cancer treatment doesn't end with choosing a therapy. Vitalix helps throughout the treatment journey:

• Treatment tracking -- Log treatment events (start, dose changes, side effects, scans, hospitalizations). The AI correlates treatment timelines with your wearable data to detect patterns -- like recovery trends after each chemo cycle or how your HRV changes during immunotherapy.
• Wearable monitoring -- Your Apple Watch, Oura Ring, or Fitbit data doesn't stop being useful because you have cancer. Sleep quality, resting heart rate, activity levels, and recovery patterns are clinically meaningful during treatment. Vitalix's AI tracks these alongside your treatment timeline.
• Symptom journal -- Log symptoms with auto-context enrichment. Each entry is tagged with what you ate, your wearable metrics, weather, medications, and sleep quality. Over time, the AI identifies trigger patterns specific to your treatment.
• Oncology specialist agents -- Vitalix has dedicated oncology support and oncology nutrition AI agents. They understand treatment cycles, energy conservation strategies, nausea management, and supplement safety during treatment. They'll never suggest a supplement without noting that oncologist approval is required.

Sharing with your care team

Everything in Vitalix can be shared with your oncologist via a secure link. They don't need a Vitalix account. The share link includes your complete profile: tumor report findings, mutations with actionability levels, matched therapies, lab results, medications, wearable trends, symptoms, and AI insights. It's a comprehensive snapshot that gives your oncologist context they wouldn't have from the tumor report alone.

You can set the link to expire, revoke it at any time, and see how many times it's been accessed.

What Vitalix is not

Vitalix is a health intelligence tool, not a medical device. It does not diagnose cancer, recommend specific treatments, or replace your oncologist. What it does is organize your data, surface options your care team can evaluate, and give you the context to have more informed conversations about your treatment.

Every AI response includes a medical disclaimer. High-risk specialties like oncology have additional safety guardrails -- the AI will never suggest stopping or changing treatment without physician guidance.

Consumer genetic test results (23andMe, AncestryDNA) should be confirmed by clinical-grade testing before making treatment decisions. Vitalix makes this clear in every genomic report.

Getting started

• Download Vitalix from the App Store or Google Play (or use the web app at app.vitalix.health)
• Upload your tumor panel PDF (FoundationOne, Tempus, Guardant, or similar)
• Optionally upload 23andMe/AncestryDNA data for germline cross-referencing
• Connect a wearable to track recovery and treatment response
• Share the link with your oncologist before your next appointment

Your tumor report has answers in it. Vitalix helps you find them.

Free during beta. Available on iOS, Android, and web.